C2N Diagnostics, LLC has entered into a non-exclusive agreement with Mayo Clinic Laboratories for the inclusion of C2N’s Precivity tests in Mayo Clinic Laboratories’ test offerings to its clients. The tests are intended for use in patients 55 and older with signs or symptoms of mild cognitive impairment or dementia, aiding healthcare providers in the detection of amyloid plaques in the brain, a hallmark of Alzheimer's disease.